Document is current

Article History

Received: 29 November 2021

Accepted: 20 February 2022

First Online: 17 March 2022

Declarations

:

: Ethics approval was granted by the Ethics Committee of the University Hospital Leuven, Belgium (S64799, S63708, S63881).

: This was a retrospective study using left-over material of samples submitted to the clinical laboratory (secondary use) for which an informed consent waiver was authorized by the ethics committee (University Hospital Leuven, Belgium) (S64799). Patients were notified of the content and aim of the study. Besides, written informed consent was obtained from six study participants according to the ethical guidelines of the Declaration of Helsinki. The Ethics Committee of the University Hospitals Leuven approved this study (S63881). Healthy controls gave informed consent (S63708).

: The authors declare no competing interests.

: Leuven COVID-19 Study Group.Maaike Cockx⁴, Glynis Frans¹, Maya Imbrechts⁵, Doreen Dillaerts⁴, Isabelle Meyts⁶, Nick Geukens⁵, Els Wauters⁷, Pieter Vermeersch¹, Joost Wauters^2,3¹Department of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.²Laboratory for Clinical Infectious and Inflammatory Disorders, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.³Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium.⁴Clinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.⁵PharmAbs, the KU Leuven Antibody Center, KU Leuven, Leuven, Belgium.⁶Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven and Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium.⁷Laboratory of Respiratory Diseases and Thoracic Surgery, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.

Free to read: This content has been made available to all.